The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Toll-Like Receptor Agonists in Cancer Therapy
Open accessAbstract
Toll-like receptors (TLRs) are pattern-recognition receptors related to the Drosophila Toll protein. TLR activation alerts the immune system to microbial products and initiates innate and adaptive immune responses. The naturally powerful immunostimulatory property of TLR agonists can be exploited for active immunotherapy against cancer. Antitumor activity has been demonstrated in several cancers, and TLR agonists are now undergoing extensive clinical investigation. This review discusses recent advances in the field and highlights potential opportunities for the clinical development of TLR agonists as single agent immunomodulators, vaccine adjuvants and in combination with conventional cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene
Poltorak, A., He, X., Smirnova, I., Liu, M.-Y., Huffel, C. V., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998) · Science · doi:10.1126/science.282.5396.2085 · Cited by 7,631
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity
Medzhitov, R., Preston-Hurlburt, P., & Janeway, C. A. (1997) · Nature · doi:10.1038/41131 · Cited by 5,590
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,193
Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J.-M., & Hoffmann, J. A. (1996) · Cell · doi:10.1016/s0092-8674(00)80172-5 · Cited by 4,043
Interleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K. J., et al. (2006) · Nature · doi:10.1038/nature04734 · Cited by 3,888
Hoshino, K., Takeuchi, O., Kawai, T., Sanjo, H., Ogawa, T., Takeda, Y., Takeda, K., & Akira, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.7.3749 · Cited by 3,374
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
Toll Pathway-Dependent Blockade of CD4 + CD25 + T Cell-Mediated Suppression by Dendritic Cells
Pasare, C., & Medzhitov, R. (2003) · Science · doi:10.1126/science.1078231 · Cited by 1,997
Kadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R. A., Bazan, F., & Liu, Y.-J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.863 · Cited by 1,964
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940
Hornung, V., Rothenfusser, S., Britsch, S., Krug, A., Jahrsdörfer, B., Giese, T., Endres, S., & Hartmann, G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4531 · Cited by 1,935
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Endotoxin-tolerant Mice Have Mutations in Toll-like Receptor 4 (Tlr4)
Qureshi, S. T., Larivière, L., Leveque, G., Clermont, S., Moore, K. J., Gros, P., & Malo, D. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.4.615 · Cited by 1,525
Kawai, T., & Akira, S. (2007) · Seminars in Immunology · doi:10.1016/j.smim.2006.12.004 · Cited by 1,404
Tian, J., Avalos, A. M., Mao, S.-Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., et al. (2007) · Nature Immunology · doi:10.1038/ni1457 · Cited by 1,372
The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens
Underhill, D. M., Ozinsky, A., Hajjar, A. M., Stevens, A., Wilson, C. B., Bassetti, M., & Aderem, A. (1999) · Nature · doi:10.1038/44605 · Cited by 1,368
TLR9 signals after translocating from the ER to CpG DNA in the lysosome
Latz, E., Schoenemeyer, A., Visintin, A., Fitzgerald, K. A., Monks, B. G., Knetter, C. F., Lien, E., Nilsen, N. J., Espevik, T., & Golenbock, D. T. (2004) · Nature Immunology · doi:10.1038/ni1028 · Cited by 1,361
Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F., & Lanzavecchia, A. (2005) · Nature Immunology · doi:10.1038/ni1223 · Cited by 1,157
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
Kim, S., Takahashi, H., Lin, W.-W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J.-L., & Karin, M. (2009) · Nature · doi:10.1038/nature07623 · Cited by 1,100
Muzio, M., Bosisio, D., Polentarutti, N., D’amico, G., Stoppacciaro, A., Mancinelli, R., van’t Veer, C., Penton-Rol, G., Ruco, L. P., Allavena, P., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.11.5998 · Cited by 1,060
COLEY, W. B. (1991) · PubMed · Cited by 965
Toll-like receptors stimulate human neutrophil function
Hayashi, F., Means, T. K., & Luster, A. D. (2003) · Blood · doi:10.1182/blood-2003-04-1078 · Cited by 939
Toll-like receptor 3 promotes cross-priming to virus-infected cells
Schulz, O., Diebold, S. S., Chen, M., Näslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y.-T., Flavell, R. A., Liljeström, P., & Reis e Sousa, C. (2005) · Nature · doi:10.1038/nature03326 · Cited by 921
Sousa, C. R. E., Hieny, S., Scharton-Kersten, T., Jankovic, D., Charest, H., Germain, R. N., & Sher, A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.11.1819 · Cited by 911
The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4
Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R., & Mitchell, T. C. (2007) · Science · doi:10.1126/science.1138963 · Cited by 896
Human Toll-Like Receptors Mediate Cellular Activation by Mycobacterium tuberculosis
Means, T. K., Wang, S., Lien, E., Yoshimura, A., Golenbock, D. T., & Fenton, M. J. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.7.3920 · Cited by 804
Jarrossay, D., Napolitani, G., Colonna, M., Sallusto, F., & Lanzavecchia, A. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200111)31:11<3388::aid-immu3388>3.0.co;2-q · Cited by 788
Toll-Like Receptor 8-Mediated Reversal of CD4 + Regulatory T Cell Function
Peng, G., Guo, Z., Kiniwa, Y., Voo, K. S., Peng, W., Fu, T., Wang, D. Y., Li, Y., Wang, H. Y., & Wang, R.-F. (2005) · Science · doi:10.1126/science.1113401 · Cited by 746
Guillot, L., Le Goffic, R., Bloch, S., Escriou, N., Akira, S., Chignard, M., & Si-Tahar, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410592200 · Cited by 689
Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8
Gorden, K. B., Gorski, K. S., Gibson, S. J., Kedl, R. M., Kieper, W. C., Qiu, X., Tomai, M. A., Alkan, S. S., & Vasilakos, J. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1259 · Cited by 683
Bernasconi, N. L., Onai, N., & Lanzavecchia, A. (2003) · Blood · doi:10.1182/blood-2002-11-3569 · Cited by 667
Speiser, D. E., Líénard, D., Rufer, N., Rubio‐Godoy, V., Rimoldi, D., Lejeune, F. J., Krieg, A. Μ., Cerottini, J., & Romero, P. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523373 · Cited by 640
Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A., Sullivan, J., Sarosdy, M. F., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251703 · Cited by 605
Vollmer, J., Weeratna, R., Payette, P., Jurk, M., Schetter, C., Laucht, M., Wader, T., Tluk, S., Liu, M., Davis, H. L., et al. (2004) · European Journal of Immunology · doi:10.1002/eji.200324032 · Cited by 595
Paulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586
The anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573
Recognition of microbial infection by Toll-like receptors
Kopp, E., & Medzhitov, R. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(03)00080-3 · Cited by 548
Toll-Like Receptors on Tumor Cells Facilitate Evasion of Immune Surveillance
Huang, B., Zhao, J., Li, H., He, K.-L., Chen, Y., Mayer, L., Unkeless, J. C., & Xiong, H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0784 · Cited by 542
Geisse, J., Caro, I., Lindholm, J., Golitz, L., Stampone, P., & Owens, M. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.11.066 · Cited by 505
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial
Vermorken, J. B., Claessen, A. M., van Tinteren, H., Gall, H. E., Ezinga, R., Meijer, S., Scheper, R. J., Meijer, C. J., Bloemena, E., Ransom, J. H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07186-4 · Cited by 504
TLR2 is expressed on activated T cells as a costimulatory receptor
Komai-Koma, M., Jones, L., Ogg, G. S., Xu, D., & Liew, F. Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400171101 · Cited by 483
TLR3 Can Directly Trigger Apoptosis in Human Cancer Cells
Salaun, B., Coste, I., Rissoan, M.-C., Lebecque, S. J., & Renno, T. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4894 · Cited by 479
A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA
Ivanov, S., Dragoi, A.-M., Wang, X., Dallacosta, C., Louten, J., Musco, G., Sitia, G., Yap, G. S., Wan, Y., Biron, C. A., et al. (2007) · Blood · doi:10.1182/blood-2006-09-044776 · Cited by 470
Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
Wiemann, B., & Starnes, C. O. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90023-x · Cited by 467
(1984) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/72.4.955 · Cited by 466
Ito, T., Amakawa, R., Kaisho, T., Hemmi, H., Tajima, K., Uehira, K., Ozaki, Y., Tomizawa, H., Akira, S., & Fukuhara, S. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020207 · Cited by 466
BCG lmmunotherapy of Malignant Melanoma: Summary of a Seven-year Experience
MORTON, D. L., EILBER, F. R., HOLMES, E. C., HUNT, J. S., KETCHAM, A. S., SILVERSTEIN, M. J., & SPARKS, F. C. (1974) · Annals of Surgery · doi:10.1097/00000658-197410000-00029 · Cited by 449
Redecke, V., Häcker, H., Datta, S. K., Fermin, A., Pitha, P. M., Broide, D. H., & Raz, E. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2739 · Cited by 448
Hasan, U., Chaffois, C., Gaillard, C., Saulnier, V., Merck, E., Tancredi, S., Guiet, C., Brière, F., Vlach, J., Lebecque, S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2942 · Cited by 435
Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer
Butts, C., Murray, N., Maksymiuk, A., Goss, G., Marshall, E., Soulières, D., Cormier, Y., Ellis, P., Price, A., Sawhney, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.011 · Cited by 428
Yang, Y., Huang, C.-T., Huang, X., & Pardoll, D. M. (2004) · Nature Immunology · doi:10.1038/ni1059 · Cited by 425
Smith, M. F., Mitchell, A., Li, G., Ding, S., Fitzmaurice, A. M., Ryan, K., Crowe, S., & Goldberg, J. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305536200 · Cited by 424
Tsuji, S., Matsumoto, M., Takeuchi, O., Akira, S., Azuma, I., Hayashi, A., Toyoshima, K., & Seya, T. (2000) · Infection and Immunity · doi:10.1128/iai.68.12.6883-6890.2000 · Cited by 409
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
Krieg, A. M. (2008) · Oncogene · doi:10.1038/sj.onc.1210911 · Cited by 388
TLR signaling by tumor and immune cells: a double-edged sword
Huang, B., Zhao, J., Unkeless, J. C., Feng, Z. H., & Xiong, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210904 · Cited by 377
Combining radiotherapy and immunotherapy: A revived partnership
Demaria, S., Bhardwaj, N., McBride, W. H., & Formenti, S. C. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.06.032 · Cited by 375
Triggering TLR signaling in vaccination
van Duin, D., Medzhitov, R., & Shaw, A. C. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.005 · Cited by 364
Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells
Stary, G., Bangert, C., Tauber, M., Strohal, R., Kopp, T., & Stingl, G. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070021 · Cited by 363
β-Defensin-2 Expression Is Regulated by TLR Signaling in Intestinal Epithelial Cells
Vora, P., Youdim, A., Thomas, L. S., Fukata, M., Tesfay, S. Y., Lukasek, K., Michelsen, K. S., Wada, A., Hirayama, T., Arditi, M., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5398 · Cited by 354
Twelve immunotherapy drugs that could cure cancers
‘Mac’ Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 341
Of mice and men: species variations of Toll-like receptor expression
Rehli, M. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02259-7 · Cited by 320
Trumpfheller, C., Caskey, M., Nchinda, G., Longhi, M. P., Mizenina, O., Huang, Y., Schlesinger, S. J., Colonna, M., & Steinman, R. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711976105 · Cited by 310
Valmori, D., Souleimanian, N. E., Tosello, V., Bhardwaj, N., Adams, S., O'Neill, D., Pavlick, A., Escalon, J. B., Cruz, C. M., Angiulli, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703395104 · Cited by 299
Self-citationTLR7 and TLR8 as targets in cancer therapy
Schön, M. P., & Schön, M. (2008) · Oncogene · doi:10.1038/sj.onc.1210913 · Cited by 296
Lebwohl, M., Dinehart, S., Whiting, D., Lee, P. K., Tawfik, N., Jorizzo, J., Lee, J. H., & Fox, T. L. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.12.010 · Cited by 293
The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol
Byrd-Leifer, C. A., Block, E. F., Takeda, K., Akira, S., & Ding, A. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200108)31:8<2448::aid-immu2448>3.0.co;2-n · Cited by 287
Czerniecki, B. J., Koski, G. K., Koldovsky, U., Xu, S., Cohen, P. A., Mick, R., Nisenbaum, H., Pasha, T., Xu, M., Fox, K. R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4038 · Cited by 266
Schaefer, T. M., Fahey, J. V., Wright, J. A., & Wira, C. R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.992 · Cited by 265
How Do Adjuvants Work? Important Considerations for New Generation Adjuvants
McKee, A. S., Munks, M. W., & Marrack, P. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.003 · Cited by 263
Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier Imiquimod
Schon, M., Bong, A. B., Drewniok, C., Herz, J., Geilen, C. C., Reifenberger, J., Benninghoff, B., Slade, H. B., Gollnick, H., & Schon, M. P. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg016 · Cited by 258
Adams, S., O'Neill, D. W., Nonaka, D., Hardin, E., Chiriboga, L., Siu, K., Cruz, C. M., Angiulli, A., Angiulli, F., Ritter, E., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.776 · Cited by 247
Self-citationClark, R. A., Huang, S. J., Murphy, G. F., Mollet, I. G., Hijnen, D., Muthukuru, M., Schanbacher, C. F., Edwards, V., Miller, D. M., Kim, J. E., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071190 · Cited by 243
Mitchell, M. S., Kan‐Mitchell, J., Kempf, R. A., Harel, W., Shau, H., & Lind, S. (1988) · PubMed · Cited by 236
Polymorphisms in Toll-like receptor genes and risk of cancer
El-Omar, E. M., Ng, M. T., & Hold, G. L. (2008) · Oncogene · doi:10.1038/sj.onc.1210912 · Cited by 233
Manches, O., Munn, D., Fallahi, A., Lifson, J., Chaperot, L., Plumas, J., & Bhardwaj, N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34823 · Cited by 228
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1
Carpentier, A., Laigle-Donadey, F., Zohar, S., Capelle, L., Behin, A., Tibi, A., Martin-Duverneuil, N., Sanson, M., Lacomblez, L., Taillibert, S., et al. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000475 · Cited by 212
Pashenkov, M., Goëss, G., Wagner, C., Hörmann, M., Jandl, T., Moser, A., Britten, C. M., Smolle, J., Koller, S., Mauch, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9129 · Cited by 210
Zhu, X., Nishimura, F., Sasaki, K., Fujita, M., Dusak, J. E., Eguchi, J., Fellows-Mayle, W., Storkus, W. J., Walker, P. R., Salazar, A. M., et al. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-10 · Cited by 194
Robinson, R. A., DeVita, V. T., Levy, H. B., Baron, S., Hubbard, S. P., & Levine, A. S. (1976) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/57.3.599 · Cited by 189
MacLean, G. D., Reddish, M. A., Koganty, R. R., Wong, T. C., Gandhi, S. S., Smolenski, M., Samuel, J., Nabholtz, J. M., & Longenecker, B. M. (1993) · Cancer Immunology Immunotherapy · doi:10.1007/bf01740902 · Cited by 184
Morton, D. L., Mozzillo, N., Thompson, J. F., Kelley, M. C., Faries, M., Wagner, J., Schneebaum, S., Schuchter, L., Gammon, G., & Elashoff, R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8508 · Cited by 177
Skokos, D., & Nussenzweig, M. C. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062305 · Cited by 174
Dudek, A. Z., Yunis, C., Harrison, L. I., Kumar, S., Hawkinson, R., Cooley, S., Vasilakos, J. P., Gorski, K. S., & Miller, J. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1443 · Cited by 173
Manegold, C., Gravenor, D., Woytowitz, D., Mezger, J., Hirsh, V., Albert, G., Al-Adhami, M., Readett, D., Krieg, A. M., & Leichman, C. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5807 · Cited by 171
Mäkelä, S. M., Strengell, M., Pietilä, T. E., Österlund, P., & Julkunen, I. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0808503 · Cited by 167
Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer
Jain, R. K. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2346 · Cited by 165
Jackson, A. M., Alexandroff, A. B., Kelly, R. W., Skibinska, A., Esuvaranathan, K., Prescott, S., Chisholm, G. D., & James, K. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb05560.x · Cited by 164
Nair, S., McLaughlin, C., Weizer, A., Su, Z., Boczkowski, D., Dannull, J., Vieweg, J., & Gilboa, E. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.6275 · Cited by 164
TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours
Conroy, H., Marshall, N. A., & Mills, K. H. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210910 · Cited by 160
Brichard, V. G., & Lejeune, D. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.038 · Cited by 160
Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists
Gorski, K. S., Waller, E. L., Bjornton-Severson, J., Hanten, J. A., Riter, C. L., Kieper, W. C., Gorden, K. B., Miller, J. S., Vasilakos, J. P., Tomai, M. A., et al. (2006) · International Immunology · doi:10.1093/intimm/dxl046 · Cited by 158
Uehori, J., Matsumoto, M., Tsuji, S., Akazawa, T., Takeuchi, O., Akira, S., Kawata, T., Azuma, I., Toyoshima, K., & Seya, T. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4238-4249.2003 · Cited by 156
Friedberg, J. W., Kim, H., McCauley, M., Hessel, E. M., Sims, P. W., Fisher, D. C., Nadler, L. M., Coffman, R. L., & Freedman, A. S. (2004) · Blood · doi:10.1182/blood-2004-06-2156 · Cited by 154
Link, B. K., Ballas, Z. K., Weisdorf, D. J., Wooldridge, J. E., Bossler, A., Shannon, M., Rasmussen, W. L., Krieg, A. Μ., & Weiner, G. J. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211304.60126.8f · Cited by 153
Hofmann, M. A., Kors, C., Audring, H., Walden, P., Sterry, W., & Trefzer, U. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318174a4df · Cited by 153
Mason, K. A., Ariga, H., Neal, R. E., Valdecanas, D. R., Hunter, N. R., Krieg, A. Μ., Whisnant, J. K., & Milas, L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.361.11.1 · Cited by 153
Bong, A. B., Bonnekoh, B., Franke, I., Schön, M. P., Ulrich, J., & Gollnick, H. P. M. (2002) · Dermatology · doi:10.1159/000063904 · Cited by 152
CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation
Milas, L., Mason, K. A., Ariga, H., Hunter, N. R., Neal, R. E., Valdecanas, D. R., Krieg, A. Μ., & Whisnant, J. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0926 · Cited by 151
Vansteenkiste, J., Zielinski, M., Linder, A., Dahabre, J., Esteban, E., Malinowski, W., Jassem, J., Passlick, B., Lehmann, F. F., & Brichard, V. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7554 · Cited by 151
Topical Imiquimod in the Treatment of Metastatic Melanoma to Skin
Wolf, I. H. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.3.273 · Cited by 141
Jarnicki, A., Conroy, H., Brereton, C. F., Donnelly, G., Toomey, D., Walsh, K., Sweeney, C. M., Leavy, O., Fletcher, J. M., Lavelle, E. C., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.3797 · Cited by 137
Schön, M. P., Wienrich, B. G., Drewniok, C., Bong, A. B., Eberle, J., Geilen, C. C., Gollnick, H. P. M., & Schön, M. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22528.x · Cited by 133
Navabi, H., Jasani, B., Reece, A., Clayton, A., Tabi, Z., Donninger, C., Mason, M. D., & Adams, M. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.10.024 · Cited by 133
Weigel, B. J., Rodeberg, D. A., Krieg, A. Μ., & Blazar, B. R. (2003) · PubMed · Cited by 133
Molenkamp, B. G., van Leeuwen, P. A. M., Meijer, S., Sluijter, B. J. R., Wijnands, P. G. J. T. B., Baars, A., van den Eertwegh, A. J. M., Scheper, R. J., & de Gruijl, T. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0050 · Cited by 131
How BCG Led to the Discovery of Immunostimulatory DNA
Tokunaga, T., Yamamoto, T., & Yamamoto, S. (1999) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.52.1 · Cited by 130
Vansteenkiste, J., Lara, P. N., Chevalier, T. L., Breton, J.-L., Bonomi, P., Sandler, A. B., Socinski, M. A., Delbaldo, C., McHenry, B. M., Lebwohl, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7097 · Cited by 130
Cancer relapse under chemotherapy: Why TLR2/4 receptor agonists can help
Garay, R. P., Viens, P., Bauer, J., Normier, G., Bardou, M., Jeannin, J., & Chiavaroli, C. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.02.018 · Cited by 129
Salazar, A. Μ., Levy, H. B., Ondra, S., Kende, M., Scherokman, B., Brown, D. S., Mena, H., Martin, N. S., Schwab, K. A., Donovan, D., et al. (1996) · Neurosurgery · doi:10.1227/00006123-199606000-00006 · Cited by 129
Green, D. S., Bodman‐Smith, M. D., Dalgleish, A. G., et al. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07664.x · Cited by 128
Toll-like Receptors in Tumor Immunotherapy
Paulos, C. M., Kaiser, A., Wrzesinski, C., Hinrichs, C. S., Cassard, L., Boni, A., Muranski, P. J., Sanchez-Perez, L. A., Palmer, D. C., Yu, Z., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1378 · Cited by 128
A Phase I Vaccine Trial with Peptides Reflecting ras Oncogene Mutations of Solid Tumors
Khleif, S. N., Abrams, S. I., Hamilton, J. M., Bergmann‐Leitner, E. S., Chen, A. P., Bastian, A., Bernstein, S. A., Chung, Y., Allegra, C. J., & Schlom, J. (1999) · Journal of Immunotherapy · doi:10.1097/00002371-199903000-00007 · Cited by 125
Molenkamp, B. G., Sluijter, B. J. R., van Leeuwen, P. A. M., Santegoets, S. J. A. M., Meijer, S., Wijnands, P. G. J. T. B., Haanen, J. B. A. G., van den Eertwegh, A. J. M., Scheper, R. J., & de Gruijl, T. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4711 · Cited by 125
Shackleton, M. J., Davis, I. D., Hopkins, W., Jackson, H. M., Dimopoulos, N., Tai, T. Y., Chen, Q., Parente, P., Jefford, M., Masterman, K., et al. (2004) · PubMed · Cited by 122
Dummer, R., Hauschild, A., Becker, J. C., Grob, J., Schadendorf, D., Tebbs, V. M., Skalsky, J., Kaehler, K. C., Moosbauer, S., Clark, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1938 · Cited by 114
Butowski, N. A., Chang, S. M., Junck, L., DeAngelis, L. M., Abrey, L. E., Fink, K., Cloughesy, T. F., Lamborn, K. R., Salazar, A. Μ., & Prados, M. D. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9693-3 · Cited by 112
Inhibition of Biologic Activity of Poly I: Poly C by Human Plasma
Nordlund, J. J., Wolff, S., & Levy, H. B. (1970) · Experimental Biology and Medicine · doi:10.3181/00379727-133-34492 · Cited by 110
Leonard, J. P., Link, B. K., Emmanouilides, C. E., Gregory, S. A., Weisdorf, D. J., Andrey, J., Hainsworth, J. D., Sparano, J. A., Tsai, D. E., Horning, S. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0815 · Cited by 108
Broomfield, S., der Most, R. G. V., Prosser, A., Mahendran, S., Tovey, M. G., Smyth, M. J., Robinson, B. W. S., & Currie, A. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803826 · Cited by 93
Torok, A. M., Bouton, A. H., & Goldberg, J. B. (2005) · Infection and Immunity · doi:10.1128/iai.73.3.1523-1531.2005 · Cited by 91
Resiquimod and other immune response modifiers as vaccine adjuvants
Tomai, M. A., Miller, R. L., Lipson, K. E., Kieper, W. C., Zarraga, I. E., & Vasilakos, J. P. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.835 · Cited by 88
A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma
Purdue, M. P., Qing Lan, B., WANG, S. S., Kricker, A., Menashe, I., Zheng, T., Hartge, P. A., Grulich, A. E., Zhang, Y., Morton, L. M., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn262 · Cited by 83
Friedberg, J. W., Kelly, J. L., Neuberg, D. S., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07773.x · Cited by 81
Butowski, N. A., Lamborn, K. R., Lee, B. L., Prados, M. D., Cloughesy, T. F., DeAngelis, L. M., Abrey, L. E., Fink, K., Lieberman, F. S., Mehta, M. P., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9705-3 · Cited by 79
Harrison, L., Skinner, S. L., Marbury, T., et al. (2004) · Archives of Dermatological Research · doi:10.1007/s00403-004-0465-4 · Cited by 78
Dols, A., Smith, J. W., Meijer, S. L., Fox, B. A., Hu, H., Walker, E., Rosenheim, S., Moudgil, T. L., Doran, T., Wood, W. J., et al. (2003) · Human Gene Therapy · doi:10.1089/104303403322124828 · Cited by 78
CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans
Haining, W. N., DAVIES, J. K., Kanzler, H., Drury, L., Brenn, T., Evans, J., Angelosanto, J., Rivoli, S., Russell, K. E. R., George, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0526 · Cited by 76
Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
Witt, P. L., Ritch, P. S., Reding, D. J., et al. (1993) · PubMed · Cited by 73
Popovič, P., DeMarco, R., Lotze, M. T., Winikoff, S. E., Bartlett, D. L., Krieg, A. Μ., Guo, Z. S., Brown, C. K., Tracey, K. J., & Zeh, H. J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8701 · Cited by 68
Select forms of tumor cell apoptosis induce dendritic cell maturation
Demaria, S., Santori, F. R., Ng, B., Liebes, L., Formenti, S. C., & Vukmanović, S. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0804478 · Cited by 67
Vaccines for lymphomas: Idiotype vaccines and beyond
Houot, R., & Levy, R. (2008) · Blood Reviews · doi:10.1016/j.blre.2008.09.001 · Cited by 66
Sharma, P., Bajorin, D. F., Jungbluth, A. A., Herr, H. W., Old, L. J., & Gnjatic, S. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181891574 · Cited by 61
Wang, J., Kobayashi, M., Han, M., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03645.x · Cited by 61
Forkhead Box P3 Regulates TLR10 Expression in Human T Regulatory Cells
Bell, M. P., Svingen, P. A., Rahman, M. K., Xiong, Y., & Faubion, W. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1893 · Cited by 58
Trakatelli, M. G., Toungouz, M., Blocklet, D., Dodoo, Y. L., Gordower, L., Laporte, M., Vereecken, P., Salès, F., Mortier, L., Mazouz, N., et al. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0056-z · Cited by 55
CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors
Mason, K. A., Neal, R. E., Hunter, N. R., Ariga, H., Ang, K. K., & Milas, L. (2006) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2006.07.024 · Cited by 52
CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response
Wooldridge, J. E., & Weiner, G. J. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200311000-00006 · Cited by 50
Silverstein, M. J. (1974) · JAMA · doi:10.1001/jama.229.6.688 · Cited by 42
Malignant Melanoma Metastatic to the Bladder
Silverstein, M. J. (1974) · JAMA · doi:10.1001/jama.1974.03230440046032 · Cited by 42
Holmberg, L., Oparin, D., Gooley, T. A., & Sandmaier, B. M. (2003) · Clinical Breast Cancer · doi:10.3816/cbc.2003.s.004 · Cited by 35
Eton, O. E., Kharkevitch, D. D., Gianan, M. A., Ross, M. I., Itoh, K., Pride, M. W., Donawho, C. K., Buzaid, A. C., Mansfield, P. F., Lee, J. E., et al. (1998) · PubMed · Cited by 30
Dumitru, C. D., Antonysamy, M. A., Gorski, K. S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0581-7 · Cited by 28
Warren, T. L., & Weiner, G. J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30147 · Cited by 21
Cited by
Aiello, A., Farzaneh, F., Candore, G., Caruso, C., Davinelli, S., Gambino, C. M., Ligotti, M. E., Zareian, N., & Accardi, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02247 · Cited by 693
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
Leventhal, D. S., Sokolovska, A., Li, N., Plescia, C., Kolodziej, S. A., Gallant, C. W., Christmas, R., Gao, J.-R., James, M. J., Abin-Fuentes, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16602-0 · Cited by 458
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
TLR agonists: our best frenemy in cancer immunotherapy
Kaczanowska, S., Joseph, A. M., & Davila, E. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012501 · Cited by 339
Activating a collaborative innate-adaptive immune response to control metastasis
Sun, L., Kees, T., Almeida, A. S., Liu, B., He, X.-Y., Ng, D., Han, X., Spector, D. L., McNeish, I. A., Gimotty, P., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.005 · Cited by 267
Self-citation
Metadata
- Authors
- Adams, S.
- Venue
- Immunotherapy
- Publisher
- Informa UK Limited
- Published
- 2009-11
- Volume
- 1
- Issue
- 6
- Pages
- 949-964
- ISSN
- 1750-743X (ISSN-L)
- 1750-7448
- OpenAlex
- W2087604357
- Cited by
- 310
- References
- 145
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.